ArticleFrontiers in chemistry2022
Synergistic and antibiofilm potential of
Article in Frontiers in chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Antibacterial and antibiofilm activities of curcumin-mediated green-synthesised silver nanoparticles against Methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.BMC biotechnology · 2026Article
- Sustainable nanomaterials for precision dental medicine: green synthesis, therapeutic applications, and future directions.Journal of nanobiotechnology · 2026Review
- Biosynthesis of fosfomycin-loaded CuO nanoparticles: evaluation of antibacterial, antibiofilm properties and molecular docking analysis against biofilm-associated proteins in MDR bacteria.Asian biomedicine : research, reviews and news · 2026Article
- Nonantibiotic Treatment of Clinical Multidrug-Resistant Bacterial Isolates Using Chitosan Nanoparticles as a Carrier for the Supernatant of Mesenchymal Stem Cells.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Harnessing biogenic nanoparticles for combating antibiotic resistance: green synthesis, mechanistic insights, and biotechnological applications.Frontiers in bioengineering and biotechnology · 2026Review
- Biogenic silver nanoparticles optimization using Plackett-Burman design and its synergistic effect with cefotaxime against multidrug resistant clinical isolates.Scientific reports · 2025Article
- Silver Nanoparticles and Antibiotics: A Promising Synergistic Approach to Multidrug-Resistant Infections.Microorganisms · 2025Review
- Synergistic Activity ofInternational journal of molecular sciences · 2025Article
- Phytonanoparticles as novel drug carriers for enhanced osteogenesis and osseointegration.Discover nano · 2025Review
- Microbial Fabrication of Quantum Dots: Mechanism and Applications.Current microbiology · 2024Review
- Review
- Article
- Nanotechnology as a Promising Approach to Combat Multidrug Resistant Bacteria: A Comprehensive Review and Future Perspectives.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hospital acquired infections caused due to ESKAPE pathogens pose a challenge for treatment due to their growing antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.